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Purpose: To assess clinical outcomes of high-dose rate interstitial brachytherapy (HIB) in localized penile carcinoma.
Material and methods: From 03/2006 to 08/2013, patients with biopsy-proven T1-T2 (<4 cm) non-metastatic localized
penile squamous cell carcinoma underwent HIB. Under general anaesthesia, after Foley catheter placement, needles
were placed in the target volume using a dedicated template. Planification was carried out with a post-implant CT-scan
to deliver a total dose of 36 Gy in 9 fractions over 5 days (in adjuvant setting) or 39 Gy in 9 fractions over 5 days
(as monotherapy). Dose-volume adaptation was manually achieved using graphical optimization. Dosimetric data and
clinical outcomes were retrospectively analyzed. Toxicities were graded using the CTC v4.0.
Results: With a median follow-up of 27 months [5.1-83], 12 patients including 8 T1a, 3 T1b and 1 T2 N0 underwent HIB
(sole therapy: 11 pts; adjuvant: 1 pt). The actuarial 5-year relapse-free, cause-specific and overall survival rates were 83%,
100% and 78% respectively. Comparing pre and post treatment evaluation, no IPSS or IIEF-5 changes were reported.
Dermatitis was reported systematically 1 month after HIB including 6 G1, 5 G2 and 1 G3. Only 1 experienced long-term
G3 successfully treated with hyperbaric oxygen therapy. One urethral meatus stenosis G3 required meatotomy.
Conclusion: In selected patients with T1-T2 localized penile cancer, HIB may be considered as an optional conservative
therapy. Longer follow-up is needed to confirm these encouraging preliminary results.Introduction
With a yearly incidence of 1 out of 100 000 men in Europe
and the United States, penile cancer remains a rare dis-
ease. Historically, the standard treatment for localized tu-
mors is partial amputation bringing psychological distress
for the men’s body [1,2]. For this reason, conservative
treatment comparable to the management of breast can-
cer has been developed with the principle of maintaining
organ function while maintaining oncological results.
These conservative treatments are based on close collab-
oration between the surgeon and the radiation oncologist
both in terms of therapeutic approach and follow-up. In-
deed, the organization of an alternate monitoring between
the urologist and radiation oncologist allows the patient to
benefit from two distinct expertise centered on the same
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unless otherwise stated.Low-dose rate (LDR) brachytherapy is a validated thera-
peutic modality in localized penile tumors T1-2 < 4 cm [3,4].
For radioprotection and dose distribution optimization con-
siderations as well as therapeutic comfort of the patient,
high-dose rate brachytherapy (HDB) has become a standard
treatment in many cancers (cervical [5], breast [6] and pros-
tate [7]). The aim of our study was to evaluate the clinical
outcome of HDB for penile cancers classified T1a, T1b or
T2 < 4 cm according to the TNM 2009 [8].
Materials and methods
We performed a retrospective, single-center, descriptive
study evaluating the results of HDB performed for pa-
tients with a localized penile cancer.
Patient characteristics
From March 2006 to August 2013, at the Centre Antoine
Lacassagne (Nice, France) with the collaboration of the
Urology department of the Nice University Hospital, 12 pa-
tients (pts) with histologically confirmed penile cancers
were treated by HDB. Preoperatively, all patients underwentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion completed if needed by a penile MRI. An ultrasound
of the inguinal area (without or with biopsy in suspected
cases of lymphadenopathy) and abdominopelvic CT were
performed to assess nodal and metastatic status in accord-
ance with the recommendations of the Cancer Committee
of the French Association of Urology (AFU) [4].
All patients presented a squamous cell carcinoma of the
penis. Circumcision was required prior to brachytherapy
and performed for all patients. Excised tissue pathological
reports (biopsies or lumpectomy) were used to determine
tumor staging. Patient characteristics are reported in
Table 1. No patient had lymph node or metastatic disease
spreading. Prior to the treatment process, patients were
given detailed information about current data, advantages
and disadvantages of this conservative technique. ThisTable 1 Clinical, technical and dosimetric data
Data Median Min - Max
Age (year) 77 [47–84]
Tumour size (mm) 25 [9–32]
Pre-op IPSS 2 [0–18]
Pre-op IIEF5 16 [5–25]
Time interval S/B (months) 120 [18–364]
Follow-up (months) 27 [5.1 - 83]
Total delivered dose (Gy) 38.5 [34–43]
EQD2αβ3 (Gy) 57.5 [47–68]
EQD2αβ10 (Gy) 46 [41–54]
Dose/f (Gy) 4 [3.5 - 4.5]
# of fractions 9 [7–10]
# needles 9 [3–12]
# plans 3 [3]
CTV (cc) 12.1 [4–42]
D90 (%) 106 [83–118]
V100 (%) 93 [78–99]
V150 (%) 40.5 [29–57]
V200 (%) 15 [11–22]
DHI 0.5 [0.46 - 0.67]
D10u (%) 126 [59–217]
D30u (%) 115 [27–177]
Pre-op IPSS: pre-operative International Prostate Symptom Score; Pre-op IIEF5:
pre-operative International Index of Erectile Function; Time interval S/B: Time
interval between surgery and brachytherapy; EQD2αβ3: equivalent dose at 2 Gy
for normal tissues (αβ3); EQD2αβ10: equivalent dose at 2 Gy for tumour (αβ10);
Dose/f: dose per fraction; # of fractions: total number of fraction; # Needles:
total number of needles; # Plans: total number of plans; CTV: clinical target
volume; D90: dose delivered to 90% of CTV expressed in percentage of the
prescribed dose; V100: CTV receiving 100% of the prescribed dose expressed
in percentage; V150: CTV receiving 150% of the prescribed dose expressed in
percentage; V200: CTV receiving 200% of the prescribed dose expressed in
percentage; DHI: Dose Homogeneity Index = [V100 – V150]/V100; D10u: dose
delivered to 10 cc of the urethral volume expressed in percentage of the
prescribed dose; D30u: dose delivered to 30 cc of the urethral volume
expressed in percentage of the prescribed dose.therapeutic approach was initially approved by a local eth-
ics committee.
HDR brachytherapy planification
After urethral catheterization with a CH 18 Foley catheter,
the penis was placed in a dedicated applicator with two
parallel templates with evenly 10 mm spaced out holes in
all directions (Figure 1). The target volume was clinically
determined. Needles insertion allowed plastic catheters
placement (Sharp Needles™; Nucletron, an Elekta com-
pany, Elekta AB, Stockholm, Sweden) through the tem-
plates in regard to the tumor volume in 1 to 3 plans
(depending on the target volume to be treated), with spe-
cial attention to not damage the urethra.
After patient recovery, CT-scan planification (without
iodine injection) was performed for the dose distribution
analysis and optimization. After delineation of the Clinical
Target Volume (CTV) and the organs at risk (mainly the
urethra) (Figure 2A), dose-volume adaptation was manually
achieved by dwell location and time variation (graphical
optimization) (OncentraBrachy™; Nucletron an Elekta Com-
pany, Stockholm, Sweden) (Figure 2B). Dose constraints
used for the CTV included V100% (volume receiving 100%
of the prescribed dose) > 95% of the prescribed dose,
V150% (volume receiving 150% of the prescribed dose) <
35% of the prescribed dose. Confluence of two V200% iso-
doses (volume receiving 200% of the prescribed dose) and
V200% diameter > 10 mm were avoided. Dose constraints
used for the urethra were V115% < 1% (urethra volume re-
ceiving 115% of the prescribed dose should be less than 1%
of the urethra volume). The prescribed dose depended on
the indication: for postoperative brachytherapy, a total dose
of 36 Gy in 9 fractions over 5 consecutive days was deliv-
ered (6 Gy at day 1 then 2 × 3.75 Gy twice daily from days
2 to 5); for brachytherapy applied as definitive treatment, a
total dose of 39 Gy in 9 fractions over 5 consecutive daysFigure 1 Intra-operative view showing the placement of the
needles through the dedicated template.
Figure 2 Post-implant CT-scan 3D reconstruction (A), dose-volume histogram (B).
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days 2 to 5. An interval of at least 6 hours was observed be-
tween the 2 daily fractions. This regimen was adapted from
a series of preoperative HDR brachytherapy used for cer-
vical cancer for which a total dose of 39 Gy in 9 fractions
was delivered over 5 days leading to a complete pathological
response rate observed on the post-operative specimen of
92% for squamous cell carcinoma [5].
HDR brachytherapy delivery
The treatment takes place in a bunker while the patient re-
mains lying in his bed. The length of each fraction depends
on the number of implanted vectors and the activity of the
radioactive source at the time of the treatment and is around
ten minutes. Throughout the duration of hospitalization, the
patient remains in a conventional non-shielded room. The
treatment is performed in optimal conditions of radioprotec-
tion for the medical staff and the patient’s family (visits pos-
sible). Indeed, the patient is carrying a radioactive source
only during the few minutes of treatment in the morning
and the afternoon. These conditions allow making the neces-
sary care (prevention of decubitus complications, local
care…) safe for nursing staff.
After the last irradiation session and patient premedica-
tion (paracetamol, tramadol, and midazolam), all the nee-
dles and the urinary catheter were removed. The patient
left the hospital with a prescription for local care for radio
dermatitis localized in the irradiated area. It usually oc-
curred in the week following the end of treatment and can
last up to 4 to 8 weeks (clear and precise information is
given to the patient regarding the occurrence of acute skin
side effects).Dosimetric analysis
Equivalent dose at 2 Gy for αβ ratio = 10 (EQD2αβ10 for
tumor tissue) and for αβ ratio = 3 (EQDαβ3 for healthy tis-
sue) were calculated. D90 (dose delivered to 90% of CTV,
expressed as a percentage of the prescribed dose) and
V100 (volume receiving 100% of the prescribed dose,
expressed as % of CTV), V150 (volume receiving 150% of
the prescribed dose expressed as % of CTV) and V200
(volume receiving 200% of the prescribed dose, expressed
as % of CTV) were studied. DHI (Dose Homogenity
Index) and D10u (dose delivered to 10% of the urethral
volume) and D30u (dose delivered to 30% of the urethral
volume) were also reported.
Analysis of oncological results
A clinical examination of the penile and inguinal areas was
conducted and completed if necessary with an inguinal
ultrasound exam, penis MRI or positron emission tomog-
raphy (PET) using fluorine 18-labeled fluorodeoxyglucose.
Treatment failure (post-treatment relapse) was defined as a
biopsy of the treated zone confirming local recurrence of
the disease or the occurrence of nodal or metastatic disease.
Local recurrence-free survival, overall and specific survival
rates were calculated. The median time to onset of relapse
was calculated from the date of treatment and the date of
onset of recurrence. For disease-free survival, 2 situations
were analyzed: local recurrence and/or regional lymph node
recurrence (inguinal and/or iliac).
Analysis of functional results
A reference pre-treatment status for urinary (International
Prostate Symptom Score - IPSS), and sexual (International
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well as skin status were established. Post-treatment toxicities
were scored according to CTCv4.0 classification [9]. At each
follow-up visit (1, 6, 12 and 24 months), the evaluation of
urinary function was based on the IPSS and the presence or
absence of urethral stricture. Sexual function was analyzed
with the IIEF-5 score. The skin condition was analyzed ac-
cording to clinical examination focusing on assessing scar-
ring, pigmentation, telangiectasia, induration or tenderness
into the irradiated volume. The rate of penile preservation
at the end of follow-up was also calculated.Statistical analyzes
Data were analyzed using software R3.0.1. Quantitative
data were represented as median, extreme, mean and
standard deviation. Qualitative data were represented as
frequency, percentage and 95% confidence interval. Over-
all survival was defined as the time between the date of
diagnosis and death from any cause. Local recurrence-free
and/or inguinal-free survivals were defined as the time be-
tween the date of diagnosis and date of local recurrence or
the date of inguinal recurrence. These data were estimated
and represented at different time intervals with their 95%
confidence using the Kaplan-Meier method. Patients were
censored at the time of death or at last follow-up. A
matched analysis by a nonparametric Friedman test was
used. The level of significance was set at a p-value < 0.05.Results
With a median follow up of 27 months [5.1 - 83], the me-
dian age was 77 years [47–84]. According to the TNM
UICC classification, patients were classified [8]: pT1a (8
pts - 66%), pT1b (3 pts - 25%) and pT2 (1 pt - 9%). The
median tumor size was 25 mm [9–32]. Nine patients
(75%) had a tumor of the glans, 3 pts (25%) had involve-
ment of the coronal sulcus. The median time between sur-
gery and brachytherapy was 120 days [18–364]. Median
pre-operative IPSS and IIEF-5 scores were respectively 2
[0–18] and 16 [5–25].Dosimetric results
The median CTV was 12.1 cc [4–42], the median D90
was 106% [83–118]. The median dose per fraction was
4 Gy [3.5 - 4.5] with a median number of fractions of 9
[7-10] (Table 1). The median total delivered dose was
38.5 Gy [34–43] corresponding to a EQD2αβ10 of 46 Gy
[41–54] and EQDαβ3 of 57.5 Gy [47–68]. The median
V100, V150 and V200 were 93% [78–99], 40.5% [29–57]
and 15% [11–22] of the CTV. The median DHI was 0.5
[0.46 - 0.67]. The median D10u and D30u were respect-
ively 126% [59–217] and 115% [27–177].Oncological results
Two patients (17%) presented an early loco-regional recur-
rence at 12 months. The first one developed an histologically
confirmed right inguinal lymph node without local recur-
rence, (treated by salvage external beam radiotherapy). The
second one presented an isolated local recurrence in the irra-
diated zone treated by salvage total amputation of the penis.
The mean time to loco-regional recurrence was 7.7 months
[6–9.4]. Because all the events occurred during the first
18 months, the actuarial rate of loco-regional recurrence free
survival, specific and overall survival at 2, 3 and 5 years are
the same. The 5-year actuarial loco-regional recurrence free
survival rate was 83% (95% [63–100]) (Figure 3a), while the
5-year actuarial overall survival rate was 78% (95% [55–100])
(Figure 3b). The 5-year actuarial specific actuarial rate was
100%, with 2 deaths being due to intercurrent causes.
Functional results
Evaluation of the urinary functional impact of brachyther-
apy was performed for all patients by comparing pre and
post-operative IPSS scores obtained 1, 6, 12 and 24 months
after brachytherapy. While the mean preoperative IPPS
score was 4, after a non-significant transient worsening at
1 month post-brachytherapy (IPSS = 6), no significant dif-
ference was noted compared to base-line for evaluations
at 6 (IPSS = 5), 12 (IPSS = 5) and 24 months (IPSS = 4)
(Figure 4A). However, 1 pt (9%) presented an urethral me-
atus stenosis requiring surgical management by dilatation
at 3 and 12 months to obtain a comparable urinary func-
tion to preoperative status.
Assessment of sexual complications was performed for
all patients by comparing pre and post-operative IIEF-5
obtained at 1, 6, 12 and 24 months after brachytherapy.
Median pre-operative IIEF-5 was 16, no significant differ-
ence was observed at 1 (IIEF5 = 16), 6 (IIEF5 = 13), 12
(IIEF5 = 13) and 24 months (IIEF5 = 13) (Figure 4B). The
mean IIEF-5 score at 2 years was 12.2 (SD 7.9) corre-
sponding to moderate erectile dysfunction.
Skin appearance observed in the treated area was analyzed
comparatively to the pre-treatment status, 1, 6, 12 and
24 months after brachytherapy, by using the CTC v4.0 clas-
sification. The assessment of skin toxicities during follow-up
showed a significant difference between pre and post-
operative assessment at one month (p < 0.01). No other
significant differences were found between the different
follow-ups at 6 (p = 0.9), 12 (p = 0.7) and 24 months (p =
0.3). Cutaneous complications encountered were mainly
grade 1 and 2 radio-dermatitis observed at 1 month in 50%
(6 pts) and 41% (5 pts) respectively (Figure 5). One patient
(9%) experienced a grade 3 skin necrosis that required 45
sessions of hyperbaric oxygen therapy to obtain complete
healing after 17 months while a retractile grade 1 fibrosis of
the glans was observed. Grades 1 telangiectasias in or next
to the irradiated area were observed in 33% of cases (4 pts).
Figure 3 Kaplan-Meier curves for local and inguinal recurrence-free survival (A) and overall survival (B).
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who presented a local recurrence treated by total amputa-
tion of the penile.
Discussion
In case of localized penile cancer, interstitial brachytherapy
after circumcision is considered as the standard conserva-
tive treatment [3,4]. Compliance with brachytherapy indi-
cation for penile cancer determines the oncological and
functional results. In fact, tumor size > 4 cm and stage ≥
T3 (invasion of the urethra) significantly increases the risk
of relapse [10-13] and skin necrosis [13,14] after brachy-
therapy. In addition, the American Brachytherapy SocietyFigure 4 Evaluation of urinary (A) and sexual (B) functional outcomes
evaluation (C).(ABS) and the Groupe Européen de Curiethérapie of the
European Society of Therapeutic Radiation Oncology
(GEC-ESTRO) recommended performing between 3 and
6 procedures per year to be able to offer this treatment
modality implying the notion of expert center [11]. Low
and pulsed-dose rate (PDR) brachytherapy represented
until recent years the reference technique [15,16]. How-
ever, the evolution of brachytherapy techniques, after-
loading machines, treatment planning software and more
stringent rules of radiation safety have positioned high-
dose rate brachytherapy as the reference technique for nu-
merous indication such cervical and prostate tumors
[5-7,15,17]. But clinical data of HDR brachytherapy forafter interstitial high-dose rate brachytherapy and skin toxicity
Figure 5 Acute skin toxicity observed 1 month after interstitial
high-dose rate brachytherapy.
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ported clinical and functional results of the largest study
of interstitial HDR brachytherapy for localized cancer of
the penis.
With a local control rate of 92%, the oncological results
reported in this series are comparable to those published
in the series of LDR/PDR brachytherapy (Table 2). In these
series, the rates of specific survival and local control vary
from 72 to 92% and from 77 to 87% respectively [12-20].
In a retrospective study, De Crevoisier et al. [14] presented
the results on 144 patients treated with LDR brachyther-
apy (median total dose of 65 Gy) over a period of 31 years.
Local recurrence-free, overall and specific survivals were
respectively 80%, 65% and 92%. Rozan et al. [16] reported
overall survival rates of 66% and 52%, specific-survival
rates of 88% and 88% and relapse-free survival rates of
78% and 67% at 5 and 10 years respectively.Table 2 Comparative clinical outcome analysis from brachyth
Authors Type n Dose (Gy) F/up (months)
Chaudhary et al. [16] LDR 23 50 21
De Crevoisier et al. [12] LDR 144 65 68
Crook et al. [17] LDR/PDR 67 60 48
Delannes et al. [18] LDR 51 50-65 65
Kiltie et al. [19] LDR 31 63.5 61.5
Mazeron et al. [20] LDR 50 60-70 36-96
Rozan et al. [15] LDR 184 63 139
Soria et al. [14] LDR 102 61-70 111
Petera J et al. [11] HDR 10 54* 20
Present serie HDR 12 36/39** 27
Type: modality of radiation therapy; LDR: Low-dose rate brachytherapy; PDR: Pulse-
patients; LC: local control; CSS: cause specific survival; F/up: follow-up in months; PP
*54 Gy in 18 fractions over 9 days.
**36 Gy in 9 fractions over 5 days (in the adjuvant setting: 6 Gy day 1 + 2 x 3.75 Gy
7 Gy day 1 + 2 x 4 Gy from day 2 to day 5).The median time to onset of loco-regional recurrence in
our study was 7.7 months [6–9.4]. Similar data are re-
ported in the literature with the notion that most of loco-
regional recurrences occur in the first two years after
treatment [18]. However, De Crevoisier et al. [14] ob-
served 10-year local, inguinal and metastatic recurrence
rates of 20%, 11% and 6% respectively. Moreover, Solsona
et al. [19] reported a late recurrence rate of 2.5%. It is
therefore necessary to recommend a prolonged surveil-
lance and provide education to patients to detect these
late local, lymph node and metastatic relapses.
The only series of HDR brachytherapy for penile cancers
has been published by Petera et al. [10]. The authors re-
ported the results of a cohort of 10 patients with squamous
cell carcinoma of the penile. Eight pts were classified as
T1N0M0, 1 pt TisN0M0 and 1 pt T1N1M0. Ninety percent
of the tumors were localized to the glans. With a median
follow up of 20 months [3.4 - 90.6], the authors reported a
loco-regional relapse-free survival rate of 100%. The total
delivered dose was 54 Gy (3 Gy/f, 2 fractions/day over 9
days). No patient presented urethral stenosis or penile ne-
crosis. Concerning sexual evaluation, patients retained
equivalent results to what was observed preoperatively. Our
shorter regimen (5 days) reports similar results in terms of
local control while significantly reducing the length of
hospitalization.
In case of local relapse after primary brachytherapy, a
salvage surgery by partial amputation of the penile, with
sufficient safety margin, leads to survival rates without
second local recurrence, equivalent to those obtained
after surgery for primary tumors. Indeed, salvage surgi-
cal series report 10-year specific survival rate ranged
from 84% to 92% similar to those described in the case
of initial surgery [19,20]. Second relapse rates after sal-
vage radical non-conservative surgery for local relapseerapy series
LC 5y (%) CSS 5y (%) Necrosis (%) Stenosis (%) PP (%)
70 0 9 70
80(10) 92(10) 26 29 72
87 83,6(10) 12 9 88
86 85 23 45 75
81 85,5 8 44 75
78 6 19 74
86 88 21 45 78
77 72 1 1 72
100 (<2y) 100 (<2y) 0 0 100
83 100 9 9 92
dose rate brachytherapy; HDR: High-dose rate brachytherapy; n: number of
: Penile preservation.
from day 2 to day 5) or 39 Gy in 9 fractions over 5 days (in sole therapy:
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organ has a deleterious psychological impact.
Regarding functional urinary outcomes, the urethra is
considered as the main organ at risk. The issue of brachy-
therapy is to limit the impact on urinary function while
preserving the oncological outcome. The measurement of
IPSS at different follow-up visits confirmed the absence of
significant degradation of urinary function after HDR
brachytherapy. In the literature, various studies of LDR/
PDR brachytherapy evaluated post-brachytherapy urinary
status by the presence or absence of urethral stenosis
(most serious urinary complication). In our series, the rate
of urinary stenosis was 9% (1 pt), whereas in the series of
LDR/PDR brachytherapy, this rate varies between 8 and
45% [12-14,16,21-23]. Generally, stenosis is treated by
dilatation or endoscopically. While urethral stenosis re-
mains the major side effect after brachytherapy, the possi-
bilities of optimizing the dose distribution to the urethra
offered by PDR/HDR brachytherapy can reduce the risk of
urinary side effects.
In our study, post-brachytherapy IIEF-5 score evaluation
compared to the pre-therapeutic status confirmed the ab-
sence of significant deterioration of the sexual function
after HDR brachytherapy. Although penile cancer and
its treatment can have a negative impact on sexual func-
tion, this functional aspect is poorly documented in the
literature. Maddineni et al. [24] reported that mutilating
treatment for penile cancer caused a significant decline in
well-being and an increase of pathological anxiety for more
than 30% of patients and psychiatric symptoms for 50% of
patients. Two thirds of patients reported a decrease in sex-
ual activity after mutilating surgery. In a retrospective study,
Crook et al. [25] reported a conservation rate of sexual
function of 40%. In their series of HDR brachytherapy,
Petera et al. [10] reported that 90% of patients preserved
their sexual function at the end of follow-up. Interestingly,
in a surgical study of 18 patients treated by partial amputa-
tion, Romero et al. [26] reported that 33% of patients con-
served a similar sexual status compared to the preoperative
period.
After penile brachytherapy, the most severe late skin
complication is necrosis. In our series, 1 pt (9%) who re-
ceived the highest dose (43 Gy; EQD2αβ3 68 Gy), pre-
sented skin necrosis successfully treated with hyperbaric
oxygen. Gomez-Iturriaga et al. [27] used also successfully
hyperbaric oxygen therapy in 7 pts with skin necrosis post-
brachytherapy. In the literature, the rate of skin necrosis
ranged between 0 to 26% of cases depending on the series
[12-14,16,21-23] while this complication has never been de-
scribed after surgery. However, acute skin complications
are much more common. In our series, 90% of patients had
radio dermatitis (G2 41%). This is a classic acute complica-
tion after radiation therapy for which the patient must be
informed. This complication should heal within 3 monthsafter brachytherapy. Other lesions observed in the treated
area were hyper-pigmentation and telangiectasia (common
complications after skin irradiation). Crook et al. [25] de-
scribed low-grade cutaneous complications such as hypo-
pigmentation, telangiectasia and fibrosis in 33% of cases.
De Crevoisier et al. [14] reported a 10-year painful ulcer-
ation rate of 26%. In the immediate post-brachytherapy
period, Petera et al. [10] noticed that radio dermatitis re-
solved in 8 weeks, while the authors did not observe any
skin necrosis. This last result could be explained by the fact
that the median CTV in the Petera study was 7 cc versus
12.1 cc in our series.
In our study, 1 pt (9%) required total amputation of
the penis due to local relapse leading to an organ preser-
vation rate of 92%. In the literature, this rate ranged be-
tween 72 and 88% [12-14,16,21-23].
The limitations of our study are essentially repre-
sented by a small number of patients (12) and a short
median follow-up (27 months), which is not sufficient
to precisely analyze the rate of late relapses occurring
after the fifth year of follow-up. On the other hand, ob-
jective analysis of post-brachytherapy urinary function
would have required before and after brachytherapy, the
use of uroflowmetry which remains in this field the
standard evaluation tool.
Conclusion
For localized cancers penile (T1-2), brachytherapy after
circumcision represented the treatment of choice. Because
of its ability to optimize the dose distribution and its low
constraints in terms of radiation protection, HDR brachy-
therapy gradually gains in popularity. For the conservative
treatment of penile cancer, this technique seems to give
promising oncological and functional results even if the
follow-up is too short to allow an accurate comparison to
the results published for LDR/PDR brachytherapy. These
results need to be confirmed by the publication of larger
series of patients with extended follow-up.
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